机构地区:[1]中国医学科学院北京协和医学院国家心血管病中心阜外医院心内科,100037
出 处:《中华心血管病杂志》2017年第12期1058-1066,共9页Chinese Journal of Cardiology
基 金:国家重点研发计划项目(2016YFC1301301)
摘 要:目的探讨左心室射血分数(LVEF)〈50%的冠心病患者经皮冠状动脉介入治疗(PCI)术后的院内及远期预后。方法采用前瞻性研究方法,连续入选2013年1至12月在阜外医院行PCI且有超声心动图LVEF资料的冠心病患者10 445例。按照LVEF值,将入选患者分为LVEF≥50%组(9 896例)和LVEF〈50%组(549例)。比较2组患者PCI术后院内及2年临床预后,并采用多因素Cox回归分析LVEF〈50%与PCI术后不良事件的相关性。结果(1)LVEF〈50%组术后院内全因死亡[1.1%(6/549)比0.2%(17/9 896),P〈0.01]、心原性死亡[1.1%(6/549)比0.1%(12/9 896),P〈0.01]、支架内血栓形成[0.7%(4/549)比0.2%(18/9 896), P〈0.01]、心肌梗死[2.4%(13/549)比1.2%(121/9 896), P〈0.05]和主要不良心脑血管事件[包括死亡、心肌梗死、血运重建、支架内血栓形成和卒中,3.6%(20/549)比1.4%(137/9 896), P〈0.01]发生率均高于LVEF≥50%组。(2)10 388例(99.5%)患者完成PCI术后2年随访。LVEF〈50%组术后2年全因死亡[4.7%(26/549)比1.0%(101/9 896), P〈0.01]、心原性死亡[4.0%(22/549)比0.5%(50/9 896), P〈0.01]、支架内血栓形成[3.1%(17/549)比0.7%(71/9 896), P〈0.01]、心肌梗死[4.2%(23/549)比1.9%(186/9 896), P〈0.01]和主要不良心脑血管事件[17.9%(98/549)比11.8%(1172/9 896), P〈0.01]发生率均高于LVEF≥50%组,而两组之间的靶血管重建、出血和卒中发生率差异均无统计学意义(P均〉0.05)。(3)多因素Cox回归分析显示,LVEF〈50%是PCI术后2年全因死亡(HR=2.47,95%CI 1.49~4.08,P〈0.01)、心原性死亡(HR=3.25,95%CI 1.79~5.90,P〈0.01)、支架内血栓形成(HR=4.19,95%CI 2.39~7.34,P〈0.01)、心肌梗死(HR=2.00,95%CI 1.26~3.16,P〈0.01)和主要不良心脑血管事件(HR=1.40,95%CI 1.13~1.74,P〈0.01)的独立危险因素。(4)倾向性评分匹配后,两组之间的术后ObjectiveTo investigate the in-hospital and long-term outcomes of patients with left ventricular ejection fraction (LVEF) 〈50% undergoing percutaneous coronary intervention (PCI) .MethodsFrom January to December 2013, 10 445 consecutive patients who underwent PCI in Fuwai Hospital and the LVEF value was available were prospectively included. The patients were divided into LVEF≥50% group (9 896 cases) and LVEF〈50% group (549 cases) . The in-hospital and 2-year clinical outcomes were compared between the 2 groups. The association between LVEF〈50% and clinical outcomes was assessed using multivariable Cox regression analysis. Results(1) Compared with LVEF ≥50% group, LVEF〈 50% group had higher rates of in-hospital all-cause death (1.1% (6/549) vs. 0.2% (17/9 896) , P〈0.01) , cardiac death (1.1% (6/549) vs. 0.1% (12/9 896) , P〈0.01) , in-stent thrombosis (0.7% (4/549) vs. 0.2% (18/9 896) , P〈0.01) , myocardial infarction (2.4% (13/549) vs. 1.2% (121/9 896) , P〈0.05) ,and major adverse cardiovascular and cerebrovascular events (MACCE) which including death, myocardial infarction, revascularization, in-stent thrombosis, and stroke (3.6% (20/549) vs. 1.4% (137/9 896) , P〈0.01) . (2) A total of 10 388 (99.5%) patients completed 2-year follow-up. Compared with LVEF ≥50% group, LVEF〈50% group had higher rates of 2-year all-cause death (4.7% (26/549) vs. 1.0% (101/9 896) , P〈0.01) , cardiac death (4.0% (22/549) vs. 0.5% (50/9 896) , P〈0.01) , in-stent thrombosis (3.1% (17/549) vs. 0.7% (71/9 896) , P〈0.001) , myocardial infarction (4.2% (23/549) vs. 1.9% (186/9 896) , P〈0.01) ,and MACCE (17.9% (98/549) vs. 11.8% (1 172/9 896) , P〈0.01) . There were no significant differences on the rates of 2-year target-vessel revascularization, bleeding and stroke between the two groups. (3) The multivariable Cox regression analysis demonstrated tha
分 类 号:R541.4[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...